Dewpoint Therapeutics
James (Jim) Shorter graduated with distinction in biology from Keble College, the University of Oxford in 1995. He received his Ph.D. from University College London in 2000. After postdoctoral studies at Yale and the Whitehead Institute for Biomedical Research at MIT, Jim established his own research program at the University of Pennsylvania. In 2018, Jim became a Professor of biochemistry and biophysics. The Shorter lab studies how to counter deleterious phase transitions in neurodegenerative disease.
This person is not in the org chart
This person is not in any offices
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.